Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 241,900 shares, a growth of 350.5% from the October 15th total of 53,700 shares. Based on an average daily volume of 268,900 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.4% of the company's shares are sold short.
Hedge Funds Weigh In On Tiziana Life Sciences
An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC increased its position in Tiziana Life Sciences Ltd (NASDAQ:TLSA - Free Report) by 24.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,387 shares of the company's stock after purchasing an additional 13,500 shares during the quarter. Zhang Financial LLC owned 0.07% of Tiziana Life Sciences worth $67,000 as of its most recent filing with the Securities and Exchange Commission.
Tiziana Life Sciences Trading Down 1.1 %
NASDAQ TLSA traded down $0.01 during mid-day trading on Tuesday, hitting $0.94. The company's stock had a trading volume of 353,068 shares, compared to its average volume of 209,462. Tiziana Life Sciences has a 52-week low of $0.41 and a 52-week high of $1.74. The stock's fifty day simple moving average is $0.94 and its two-hundred day simple moving average is $0.93.
About Tiziana Life Sciences
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
See Also
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
